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Abstract
Background: Influenza viruses are a major cause of morbidity and mortality around the world. More recently, a
swine-origin influenza A (H1N1) virus that is spreading via human-to-human transmission has become a serious
public concern. Although vaccination is the primary strategy for preventing infections, influenza antiviral drugs play
an important role in a comprehensive approach to controlling illness and transmission. In addition, a search for
influenza-inhibiting drugs is particularly important in the face of high rate of emergence of influenza strains
resistant to several existing influenza antivirals.
Methods: We searched for novel anti-influenza inhibitors using a cell-based neutralization (inhibition of virus-
induced cytopathic effect) assay. After screening 20,800 randomly selected compounds from a library from
ChemDiv, Inc., we found that BPR1P0034 has sub-micromolar antiviral activity. The compound was resynthesized in
five steps by conventional chemical techniques. Lead optimization and a structure-activity analysis were used to
improve potency. Time-of-addition assay was performed to target an event in the virus life cycle.
Results: The 50% effective inhibitory concentration (IC50) of BPR1P0034 was 0.42 ± 0.11 μM, when measured with
a plaque reduction assay. Viral protein and RNA synthesis of A/WSN/33 (H1N1) was inhibited by BPR1P0034 and
the virus-induced cytopathic effects were thus significantly reduced. BPR1P0034 exhibited broad inhibition
spectrum for influenza viruses but showed no antiviral effect for enteroviruses and echovirus 9. In a time-of-
addition assay, in which the compound was added at different stages along the viral replication cycle (such as at
adsorption or after adsorption), its antiviral activity was more efficient in cells treated with the test compound
between 0 and 2 h, right after viral infection, implying that an early step of viral replication might be the target of
the compound. These results suggest that BPR1P0034 targets the virus during viral uncoating or viral RNA
importation into the nucleus.
Conclusions: To the best of our knowledge, BPR1P0034 is the first pyrazole-based anti-influenza compound ever
identified and characterized from high throughput screening to show potent (sub-μM) antiviral activity. We
conclude that BPR1P0034 has potential antiviral activity, which offers an opportunity for the development of a new
anti-influenza virus agent.
Background
Influenza viruses are respiratory pathogens that affect
humans and are responsible for substantial morbidity,
mortality, and decreased productivity. Vaccination pro-
vides the primary protection from influenza virus infec-
tions. Because of the continuous evolution of major viral
antigens, vaccine strains must be selected annually.
Therefore, vaccine production may not satisfy the need
during an influenza pandemic. Antiviral drugs provide a
valuable addition to the options available to control influ-
enza infections. Two classes of these antiviral drugs, ada-
mantanes and neuraminidase (NA) inhibitors, are
currently prescribed for the prophylaxis and treatment of
influenza infections [1]. Adamantanes (amantadine and
rimantadine) target the proton channel formed by the
viral M2 protein. Because this protein is absent in influ-
enza B viruses, adamantanes have no antiviral effect on
this virus type [2]. The rapid spread of resistance to
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any medium, provided the original work is properly cited.adamantanes in recent years [3,4] has diminished the use-
fulness of this class of drugs. Two NA inhibitors, orally
bioavailable oseltamivir and inhaled zanamivir, are the
only drugs currently recommended for the treatment of
both influenza A and B virus infections. Mutations identi-
fied in the NAs of viruses selected in the presence of NA
inhibitors vary depending on the NA antigenic type/sub-
type and on the drug used [5]. NA is a surface antigen
containing an enzymatic active site that is targeted by NA
inhibitors. Therefore, viruses with reduced drug suscept-
ibility can emerge as a result of drug use and/or natural
genetic variation in NA. A noticeable increase in the emer-
gence of drug-resistant influenza A (H1N1) viruses has
been observed in the United States, starting from the end
of October of 2007 and spreading widely in 2008. These
findings are consistent with reports of the emergence of
oseltamivir resistance in influenza A (H1N1) viruses in
China, Europe, and other countries [6,7]H. H5N1 viruses
resistant to oseltamivir also pose a threat to the public
[8-10]. More recently, a swine-origin influenza A (H1N1)
virus that is being spread via human-to-human transmis-
sion has become a serious public concern around the
world [11-14]. A search for influenza-inhibiting drugs is
thus particularly important in the face of new pandemic
strains and high rate of emergence of influenza strains
resistant to several existing influenza antivirals. Cell-based
primary screening antiviral assays have the ability to simul-
taneously screen broad classes of compounds against the
functions of multiple viral targets, as well as screen for
toxicity [15-17]. The development of a robust and large-
scale anti-influenza virus cell-based assay has been estab-
lished by Noah et al [16]. The objective of this study was
to identify novel anti-influenza inhibitors using a similar
cell-based neutralization (inhibition of virus-induced cyto-
pathic effect) assay. After screening 20,800 randomly
selected compounds from a library, we found that
BPR1P0034 has potent inhibitory activity (Fig. 1).
Methods
Cell lines, virus strains, and chemicals
Madin-Darby canine kidney (MDCK), Vero, and human
rhabdomyosarcoma (RD) cells were maintained in
Dulbecco’s modified Eagle’sm e d i u m( D M E M )
supplemented with 10% heat-inactivated fetal bovine
serum, penicillin (100 U/mL), and streptomycin (100
μg/mL), and the MDCK cells were also fed with addi-
tional L-glutamine (2 mM; Gibco) and a nonessential
amino acid mixture (0.1 mM; Gibco). Both cell lines
were maintained at 37°C in an incubator under 5% CO2
in normal air. Influenza virus A/WSN/33 and other
strains (Table 1) were propagated in MDCK cells and
enteroviruses and echovirus 9 were amplified in RD
cells. Amantadine was purchased from Sigma-Aldrich
(St Louis, MO, USA) and zanamivir (Relenza) was
synthesized and provided by Dr Chun-Cheng Lin
(National Tsing-Hua University, Taiwan).
Viral titer determination by plaque assay
Monolayer MDCK cells (6 × 10
5 cells/well) were washed
once with Dulbecco’s phosphate-buffered saline (DPBS),
and infected with a serially diluted viral suspension. After
adsorption for 1 h at 37°C, the viral suspension was
replaced with overlay medium, E0 (DMEM with penicillin
[100 U/mL], streptomycin [100 μg/mL], L-glutamine [2
mM], and nonessential amino acid mixture [0.1 mM])
containing 2.5 μg/mL trypsin and 0.3% agarose. After
incubation for 2-3 days at 37°C under 5% CO2, the cells
were fixed with 10% formaldehyde and then stained with
1% crystal violet. The titer of the virus was expressed in
plaque-forming units (PFU) per milliliter.
Neutralization test and IC50 determination
Tissue culture plates (96-well) were seeded with 2.4 ×
10
4cells/well and incubated for 16-20 h at 37°C under
5% CO2. The cells were washed once with DPBS, then
infected with virus (MOI 3 × 10
-5), and were overlaid
with 50 μL of DMEM containing varying concentrations
of test compounds. After incubation at 37°C under 5%
CO2 for 72 h, the cells were treated with 100 μLo f4 %
paraformaldehyde for 20 min, and stained with 0.1%
crystal violet for 15 min at room temperature. The den-
sity of the cells was measured at 570 nm with a VIC-
TOR
3 enzyme-linked plate reader (PerkinElmer). The
concentration of compound necessary to reduce the
virus-induced cytopathic effect (CPE) by 50%, relative to
the virus control was expressed as the IC50.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay
MDCK cells (2.4 × 10
4 cells/well) were seeded in a 96-
well plate and incubated at 37°C overnight before the
addition of varying concentrations of test compounds.
After incubation at 37°C for 72 h, the cells were washed
with Hank’s balanced salt solution (HBSS; Gibco) and
50 μL/well of MTT solution (5 mg/mL) was added, and
then the cells were incubated at 37°C for 3 h. The med-
ium was carefully withdrawn without touching the cells.
Figure 1 Chemical structure of BPR1P0034.
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tal violet, and the absorbance at OD570 was read with an
ELISA reader. The 50% cytotoxic concentration (CC50)
of the drug resulted in 50% cell death compared with
that in the no-drug control. The CC50 was determined
according to the Reed-Muench method.
CPE inhibition test
MDCK cells (2.5 × 10
6 cells/well) were seeded in a 6 cm
tissue culture dish, grown to confluence, and then chal-
lenged with virus (multiplicity of infection [MOI] = 5).
After adsorption of virus for 1 h at 37°C, the cells were
washed with HBSS, after which E0 containing the test
compound was added. After incubation for 10 h, the
CPE was evaluated under a microscope.
Plaque reduction assay
MDCK cells (6 × 10
5 cells/well) were seeded into six-well
tissue culture plates and incubated overnight. The cells
were incubated with influenza virus at approximately 50
PFU/well with or without different concentrations of the
test compound. After adsorption of the virus for 1 h at
37°C, the viral suspension was removed and the cells
were washed with HBSS. The cells were then overlain
with E0 containing 0.3% agarose with or without the test
compound. After incubation for 2-3 days at 37°C under
5% CO2, the cells were fixed with 10% formaldehyde and
then stained with 1% crystal violet. The numbers of pla-
ques were counted and the percentages (plaque number
in the presence of compounds relative to that of
untreated control) of antiviral activity were calculated.
Time-of-addition assay
MDCK cells (6 × 10
5 cells/well) were seeded in six-well
tissue culture plates and incubated overnight. The cells
were challenged with virus (MOI = 5) on ice for 1 h.
After adsorption of the virus for 1 h, the viral suspen-
sion was removed and the cells were washed with
HBSS, then replenished with fresh E0 medium (pi = 0).
T h et e s tm e d i u mc o n t a i n i n g1μM of compound was
added during the periods -2 to -1 h (preadsorption), -1
to 0 h (adsorption), 0 to 2 h, and 2 to 10 h. After each
incubation period, the monolayer was washed with
HBSS and incubated with fresh medium until 10 h post-
infection (p.i.). The supernatant was collected and the
viral yield was determined by plaque assay.
Western blot
MDCK cells (2 × 10
6)w e r es e e d e di na6c md i s ha n d
incubated overnight. The cells were infected with
Table 1 Antiviral activity of BPR1P0034.
Concentration (μM)
BPR1P0034 Amantadine Zanamivir
IC50 CC50
c IC50 IC50
Cytotoxic effect
MDCK 6.75 ± 0.08
Influenza virus
A/WSN/33 (H1N1)
b 0.21 ± 0.07 > 25 0.06 ± 0.02
A/Udorn/72 (H3N2)
a 2.11 ± 0.41 0.98 ± 0.15 0.67 ± 0.23
A/TW/83/05 (H3N2)
a 1.38 ± 0.08 > 25 0.92 ± 0.03
A/TW/785/05 (H1N1)
a 0.92 ± 0.11 0.38 ± 0.24 1.06 ± 0.98
B/TW/710/05
b 8.11 ± 3.98 > 25 0.03 ± 0.02
B/TW/70325/05
b 1.94 ± 0.72 > 25 0.02 ± 0.01
B/TW/99/07
b 8.90 ± 4.16 > 25 0.10 ± 0.01
Enterovirus 71
b
TW/1743/98 > 40 > 20 ––
TW/4643/98 > 20 > 20 ––
Echovirus 9
b >2 0 >2 0 ––
MDCK cells or Vero cells were infected with influenza virus and EV71, respectively, and incubated with different concentrations of BPR1P0034.
IC50was determined with a plaque reduction assay
a or a neutralization assay
b
cCC50 was determined with an MTT assay
–, not determined
The values are means ± SD of 2–3 independent experiments.
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without BPR1P0034 (5 μM), and were harvested at var-
ious times p.i. The total cell lysate was resolved with
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis and the proteins were transferred to polyvinylidene
difluoride membranes, which were incubated with pri-
mary antibody for 1 h and then with the appropriate sec-
ondary antibody. The proteins were detected using an
enhanced chemiluminescence western blotting detection
system (Millipore, Billerica, MA, USA). Rabbit polyclonal
antibodies directed against nucleocapsid protein (NP) of
influenza A virus or against glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were from Abcam (ab46967)
and Santa Cruz Biotechnology (sc-25778), respectively.
Indirect immunofluorescence assay
MDCK cells (1 × 10
5 cells) were seeded on a coverslip
and incubated overnight. The cells were infected with
influenza virus A/WSN/33 (MOI = 5) for 1 h with or
without BPR1P0034 (5 μM) and the coverslips were
fixed with 4% paraformaldehyde for 20 min at room
temperature at various p.i. time points. The coverslips
were incubated with blocking solution (0.5% bovine
serum albumin in phosphate-buffered saline) for 1 h at
room temperature and then reacted with rabbit anti-NP
primary antibody diluted in blocking solution for 1.5 h.
After the coverslips had been washed three times with
blocking solution, they were incubated with the appro-
priate Alexa-Fluor-488-labeled secondary antibody and
the fluorescence was evaluated with a Zeiss Axiovert
200 M microscope.
Measurement of Viral RNA Synthesis by Quantitative
Reverse Transcription-Polymerase Chain Reaction
(Q-RT-PCR)
MDCK cells were infected with A/WSN/33 at an MOI
of 5, and total RNA was extracted from cells at various
times by using TRIzol (Invitrogen, Carlsbad, CA, USA).
The first strand of cDNA was synthesized by using
MMLV reverse transcriptase (Invitrogen). Real time Q-
RT-PCR was performed in a 20 μl reaction mixture con-
taining 50 nM forward and reverse primers, 1 × SYBR
green master mix (Protech Technology Enterprise, Tai-
wan), and various amounts of template. Fluorescence
emitted by SYBR green was detected by using the ABI
StepOne Plus sequence detection system (Applied Bio-
systems, Foster City, USA). To quantify changes in gene
expression, the ΔCt method was used to calculate rela-
tive changes normalized against the GAPDH gene, as
described in User Bulletin No. 2 (Applied Biosystems).
The Ct is defined as the cycle at which fluorescence is
determined to be significantly greater than background.
The ratio of viral RNA to the internal control was nor-
malized to the RNA level at 0 h p.i, which was
arbitrarily set to 1. M1 forward primer, 5’GAC CAA
TCC TGT CAC CTC; M1 reverse primer, 5’GAT CTC
CGT TCC CAT TAA GAG; GAPDH forward primer,
5’AAG AAG GTG GTG AAG CAG GC; GAPDH
reverse primer, 5’TCC ACC ACC CTG TTG CTG TA.
General synthesis of BPR1P series (see Additional
file 1).
Results
BPR1P0034 inhibits influenza virus in a cell-based
neutralization assay
Randomly selected 20,800 compounds from a library
collection purchased from ChemDiv, Inc., (San Diego,
CA, USA, http://www.chemdiv.com) were screened for
their capacity to inhibit influenza-virus-induced cell
death in a neutralization assay. Influenza virus A/WSN/
33 was used and the compounds were tested at a con-
centration of 10 μM in an assay using MDCK cells, in
which GS4071 (oseltamivir carboxylate) was used as the
positive control. A reduction in virus-induced cell death
indicated antiviral activity. BPR1P0034 (Fig. 1) was one
of several initial hits displaying an IC50 of less than 10
μM, with no apparent cytotoxicity. The IC50 of
BPR1P0034 was 0.21 ± 0.07 μM( T a b l e1 ) .T h em o r -
phology of the inhibition of influenza-virus-infected CPE
i nt h ep r e s e n c ea n da b s e n c eo ft e s tc o m p o u n do rv i r u s
was evaluated by microscopy. The influenza-virus-
infected MDCK cells became rounded and eventually
became detached. This CPE was significantly reduced
when 1 μM BPR1P was added (data not shown). There
was no obvious change in cell morphology when the
cell culture medium contained the same concentration
of BPR1P.
Lead optimization
The hit compound was optimized by preparing analo-
gues and further refined by examining their structure-
activity relationships (SARs). The lead compound struc-
ture was divided into three pharmacophores, R
1,R
2, and
R
3, and 34 analogues were prepared for the SAR study
(Additional file 2). The activity of these analogues was
determined with a cell-based neutralization assay. By
varying the hydrophobic part of the pyrazole scaffold in
R
1, we prepared more than 10 analogues, the most
potent of which contained the acenaphthene group
(BPR1P0034). We varied R
2 of the lead compound by
changing the hydrazone part, thus preparing 18 analo-
gues. From the assay results, we found that the presence
of a nitro group at the ortho position was essential for
anti-influenza-virus activity (BPR1P0034). By changing
pharmacophore R
3, we prepared four analogues, three of
which showed moderate activity (5 < IC50 <2 5μM).
W es y n t h e s i z e dat o t a lo f3 4a n a l o g u e s .N i n eo ft h e m
showed moderate activity and eight showed good
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synthesized was the lead compound BPR1P0034, which
exhibited an IC50 of 0.21 ± 0.07 μM in the neutraliza-
tion assay.
Mechanism-of-action studies
We also examined the broad-spectrum activity of this
compound by subjecting it to a bioevaluation study
against a variety of strains and viruses, including influ-
enza A and B viruses (four and three strains, respec-
tively, and most of them were recent clinical isolates),
enterovirus 71 (two serotypes), and echovirus 9. We
used amantadine and zanamivir (Relenza) as positive
controls. The results are shown in Table 1. As shown,
zanamivir showed excellent activity against both influ-
enza A and B viruses. Amantadine showed no activity
against influenza B viruses, as expected. Our compound
exhibited similar activity against both A and B viruses
demonstrating that it inhibited not only laboratory-
adapted WSN strain with long passage history but also
several strains isolated after 2005. However, no antiviral
activity against enteroviruses or echovirus 9 was
observed. To investigate the possible time-dependent
inhibitory effects on influenza replication, BPR1P0034
was added to monolayers of infected cells before or
after viral adsorption, and the virus yield was assessed
using the plaque formation assay (Fig. 2). When the
compound was added before viral adsorption (from -2
to 0 h p.i.), no reduction in viral yield was detected.
However, BPR1P0034 displayed a significant inhibitory
effect on influenza virus when added after viral adsorp-
tion, particularly in the early stage (from 0 to 2 h p.i.),
suggesting that BPR1P0034 affects the early steps of the
replication cycle, such as uncoating or vRNA importa-
tion into the nucleus but this requires further evalua-
tion. At this concentration, viral plaque formation was
clearly inhibited (Fig. 3).
We tested the inhibitory activity of BPR1P0034 against
influenza viral polymerase using a plasmid-based ribo-
nucleoprotein (RNP) assay. In brief, we added
BPR1P0034 to HEK293 cells coexpressing influenza
virus A/WSN/33 (H1/N1) polymerase complex proteins,
including PA, PB1, PB2, and NP, together with the
reporter plasmid, pPOLI-CAT-RT. The reporter plasmid
contained a vRNA-like RNA encoding the reporter gene
for chloramphenicol acetyltransferase (CAT), in the
negative sense, flanked by the 5’ and 3’ noncoding
regions of the NS vRNA segment of the influenza virus
[18]. BPR1P did not inhibit the RNA-dependent RNA
polymerase (RdRp) at concentrations of up to 10 μM
( d a t an o ts h o w n ) .W ec o n c l u d et h a tt h ep o l y m e r a s eo f
influenza virus A/WSN/33 (H1N1) may not be the pri-
mary molecular target of BPR1P0034, based on the cell-
b a s e dR d R pa s s a y .W ea l s oa ddressed the activity of
BPR1P0034 in inhibiting NA using an in vitro neurami-
nidase inhibition assay [19]. A formaldehyde-inactivated
influenza virus suspension from MDCK cells infected
with influenza virus was produced and used in the neur-
aminidase inhibition assay. To evaluate the inhibitory
activity of BPR1P0034, inactivated virus supernatant was
preincubated with the test compounds for 30 minutes at
30°C. The enzymatic reactions were performed for one
hour at 37°C, terminated, and the fluorescence intensity
measured using the fluorogenic substrate 2’-(4-methy-
lumbelliferyl)-a-D-N-acetylneuraminic acid [20] with a
spectrofluorometer. The viral titer was below the detec-
tion limit, with no reduction in NA activity (results not
shown). The effects of BPR1P0034 on influenza virus
were further evaluated with a plaque reduction assay.
BPR1P0034 at various concentrations was evaluated in
viral plaque reduction assays for influenza virus A/
WSN/33. BPR1P0034 dose dependently reduced the
PFU produced by infection of MDCK cells with
Figure 2 Time of addition of BPR1P0034.( A )M D C Kc e l l sw e r e
inoculated with influenza A/WSN/33 virus at MOI = 5. BPR1P0034
was added at the indicated times. Viral infection was performed
between –1 h and 0 h. (B) After each incubation period, the test
medium containing 1 μM of compound was removed and the cells
were incubated with fresh medium until 10 h postinfection. The
supernatant was collected and viral yield was determined by plaque
assay. This is a representative result of two independent
experiments.
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formation was estimated to be 0.42 ± 0.11 μM. The IC50
of GS4071 was approximately 40 nM (not shown).
Inhibition of viral protein and RNA synthesis
In the time-of-addition assay, BPR1P0034 demonstrated
the most potent antiviral activity at 0-2 h p.i., when viral
replication and translation actively occur (Fig. 2). We
then investigated whether BPR1P0034 inhibited viral
protein and RNA synthesis in an infectious cycle. In a
time course experiment, MDCK cells were infected with
influenza virus (MOI = 0.5) and were treated with or
without BPR1P0034. Cells were harvested at indicated
times p.i. and subjected to western blotting using an
antibody specific against NP protein. The viral protein
produced by the influenza virus (represented by NP)
was evident 2 h p.i., and its expression persisted there-
after. The NP produced by influenza virus (Fig. 4A,
lanes 6, 9, 12, and 15) was reduced in BPR1P0034-trea-
ted cells compared with that in untreated cells (a mean
of 2.06 compared to a mean of 1.29 constituting a dif-
f e r e n c eo f1 . 6 0f o l da t8hp . i .f r o mt w oi n d e p e n d e n t
e x p e r i m e n t s )( F i g .4 A ,l a n e s5 ,8 ,1 1 ,a n d1 4 ) .T h i ss u g -
gests that the reduction in viral protein production is
attributed to the inhibition by BPR1P0034 of viral trans-
lation. We used immunofluorescence microscopy to
confirm this observation. MDCK cells were infected
with influenza virus A/WSN/33 (MOI = 5) and incu-
bated with or without 5 μM BPR1P0034 in the adsorp-
tion and postinfection stages. The cells were fixed at 3
or 6 h p.i. and reacted with primary anti-NP antibody
and evaluated by immunofluorescence microscopy. NP
was distributed not only in the cytoplasm but also in
the nuclei of the infected cells (Fig. 4B). The expression
of NP was significantly reduced in the presence of
BPR1P0034. We also investigated viral RNA synthesis in
Figure 3 BPR1P0034 reduced influenza virus production. MDCK cells were infected with influenza virus A at 50 PFU/well. Different
concentrations of BPR1P0034 were added at the stages of viral adsorption and postinfection. (A) The effect of BPR1P0034 on viral plaque
formation. (B) Quantification of viral plaques treated with serial dilutions of BPR1P0034. This is a representative result of two independent
experiments. The y-axis represents percentage of plaque reduction compared with the virus alone control, set as 100%.
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33 (MOI = 0.5) and incubated with or without 5 μM BPR1P0034 in the adsorption and postinfection stages. The sample was subjected to
western blotting (A), immunofluorescence microscopy (B), or quantitative PCR (C). (A) The infected cells were harvested at the times indicated
and evaluated by western blotting using an anti-NP antibody. GAPDH was used as the loading control. This is representative of two
independent experiments. (B) Influenza A/WSN/33 virus (MOI = 5)-infected MDCK cells on coverslips were incubated with or without BPR1P0034
during viral adsorption and after infection. The cells were fixed for the indicated times and reacted with primary anti-NP antibody and Alexa-
Fluor-488-labeled secondary antibody. The production of viral protein, represented by NP, was detected by immunofluorescence microscopy.
(Row A) Cells infected with influenza virus and harvested at 3 h p.i; (Row B) The same as (Row A) but in the presence of BPR1P0034; (Row C)
Cells infected cells and harvested at 6 h p.i; (Row D) The same as (Row C) but in the presence of BPR1P0034. (C) The MDCK cells were
challenged with virus in the presence or absence of BPR1P0034 and total RNA was extracted at indicated times. Equal amounts of total RNA (3
μg) were used for quantitative RT-PCR analysis. To quantify the changes in gene expression, the ΔCt method was used to calculate relative
changes which were normalized to the GAPDH gene. The ratio of viral RNA to the internal control was normalized to the RNA level at 0 h p.i,
which was arbitrarily set to 1.
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without BPR1P0034. Total RNA was extracted and sub-
jected to quantitative PCR analysis in the infected
MDCK cells at 3, 6, and 9 hours post adsorption. Viral
RNA was significantly reduced by about 55-68% when
the cells were treated with compound at a concentration
that inhibited virus-induced CPEs (Fig. 4C).
Discussion
There is an urgent need for new anti-influenza drugs
and the objective of this study was to identify novel
inhibitors from an in-house database. After screening
20,800 structurally diverse compounds, we found that
BPR1P0034 has potent inhibitory activity against influ-
enza virus. This is the first compound ever identified
and characterized from high throughput screening pos-
sessing sub-micromolar anti-influenza activity [16]. Pyr-
azole and its derivatives have been developed as antiviral
compounds [21-24]. Two new class pyrazole compounds
with improved stability were synthesized from aryl
diketo acid which was a potent and selective inhibitor
against HIV. Zeng et al, reported these compounds
exhibited antiviral activity with IC50 below 10 μM[ 2 1 ] .
Novel pyrazole compounds were developed via SAR
study to inhibit West Nile virus and HSV-1 but the anti-
viral activity (IC50) never reached optimal level (sub-μM
concentration) [22-24]. To the best of our knowledge,
BPR1P0034 is the only pyrazole compound that pos-
sesses the best potent antiviral activity (sub-μM) thus
far.
In a mechanistic study, viral yield was reduced by 90%
when this compound was added at 0-2 h p.i. in a time-
of-addition experiment (Fig. 2). This point represents an
early stage of viral infection and many preparatory steps
for viral replication come into play at this time, such as
viral internalization, uncoating, vRNA importation into
the nucleus, and primary transcription and translation.
Viral yield was also reduced during incubation with
BPR1P0034 at 2-10 h p.i. but less dramatically than dur-
ing incubation at 0-2 h p.i., although the incubation per-
iod was longer. Because viral transcription and
translation occur at 2-4 h p.i., we predict that the inhibi-
tion of viral proteins before 4 h p.i. will disrupt the
expression of late proteins, such as hemagglutinin and
NA, involved in packaging and budding. We also
hypothesize that BPR1P0034 is a general (nonspecific)
inhibitor that inhibits viral infection not only in the
early stages but also in the late stages (5-12 h p.i.) of
infection, in processes such as RNP export from the
nucleus, the glycosylation and transport of viral proteins,
NA maturation, and viral packaging. However, we can-
not exclude the possibility that BPR1P0034 targets cellu-
lar factor(s), provoking a multitude of signaling
processes in infected cells that may have key functions
in the antiviral response [25]. We tested the inhibitory
activity of BPR1P0034 against influenza polymerase in a
cell-based assay and found that this compound did not
inhibit influenza RNP at concentrations of up to 10 μM,
at which concentration plaque formation was completely
inhibited (data not shown). The activity of BPR1P0034
in inhibiting NA was tested in an in vitro neuraminidase
inhibition assay [19] and it did not inhibit the enzymatic
activity of NA at concentrations of up to 40 μM (data
not shown). In conclusion, BPR1P0034 is neither a poly-
merase inhibitor nor an NA inhibitor.
In the time-course experiment, viral NP synthesis was
inhibited from as early as 2 h p.i. and remained inhib-
ited for 12 h p.i. (Fig. 4A). The inhibition of viral pro-
tein synthesis was further confirmed with
immunofluorescence microscopic and quantitative PCR
data (Fig. 4B, C). These findings are consistent with the
results of the time-of-addition assay, in which
BRP1P0034 acted at an early stage of viral infection.
The efficacy of current treatments is limited or uncer-
tain in some populations and situations. For example,
oseltamivir has lower clinical effectiveness against influ-
enza B than against influenza A infections in children
[26-28]. Moreover, the frequency of viral resistance to
M2 and NA inhibitors has increased rapidly among sea-
sonal influenza viruses and is now so widespread that it
presents a clinical problem [3,4]. The search for alterna-
tive antiviral inhibitors with different target sites has
thus become an urgent issue. In this study, we have
identified a novel anti-influenza compound BPR1P0034
with an unidentified mode-of-action. It will be interest-
ing to elucidate the underlying mechanism accounting
for its antiviral activity. With the established assays
[29,30], we tested and found that BPR1P0034 did not
inhibit NA or the cell-based viral RNP activity (data not
shown). Separate studies will be needed to explore if
BPR1P0034 would directly inhibit the functions of virus-
encoded proteins such as the M2 ion channel. Very
recently, a number of host factors were shown needed
for influenza virus replication in host cells [31-33]. Inhi-
bition of influenza virus could be achieved through
RNAi knock-down or pharmacological inhibition of the
essential host factors. Thus, it is also possible that
BPR1P0034 is able to interfere with these essential host
functions that are needed for the replication of influenza
virus inside the cells. Overall, BPR1P0034 may serve as a
starting point for the development of a novel class of
anti-influenza virus drugs.
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